Cihan Ay "Cancer and VTE: mechanistic underpinnings of risk"
Cancer is a strong and independent risk factor for thrombosis. The epidemiology, risk factors and molecular mechanisms of cancer-associated thrombosis (CAT) differ from venous thromboembolism in the general population.
Marc Carrier "Medical treatment of cancer-associated VTE in 2018"
Recent clinical trials have assessed the role of direct oral anticoagulants (DOACs) for the management of cancer-associated thrombosis (CAT).
Supported by an unrestricted educational grant from: Bayer
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.